UCB's Brivaracetam Positive in Phase III Epilepsy Study - Analyst Blog


UCB SA ( UCBJF ) announced positive top-line results from a phase III study (n=768) on epilepsy candidate, brivaracetam. Brivaracetam achieved a statistically significant reduction in partial-onset seizure frequency and improved responder rates in the patients compared to placebo.

In the randomized, double-blind, placebo-controlled, multi-center, parallel-group phase III study (N01358) UCB evaluated the efficacy and safety of brivaracetam, for a 12-week period, as an adjunctive treatment in patients (16 − 80 years of age) suffering from focal epilepsy with partial-onset seizures, and who have not achieved full control despite undergoing treatment with one or two concomitant antiepileptic drugs. This study was the last one scheduled under the phase III program on brivaracetam.

The phase III program comprises four studies, N01252, N01253, N01254 and N01358. In the aforementioned N01358 study, brivaracetam's tolerability was consistent with that found in the previous studies.

Epilepsy is a chronic neurological disorder that affects nearly 65 million people across the world. According to the press release issued by UCB, almost 1 out of 26 people are expected to develop epilepsy in their lifetime.

On the basis of results from the phase III program, UCB intends to file for approval of brivaracetam in the U.S. and the EU in early 2015.

A drug already approved as an adjunctive treatment of partial-onset seizures in adults is GlaxoSmithKline ( GSK )− Valeant Pharmaceuticals ' ( VRX ) Potiga (brand name in Europe: Trobalt).

We are encouraged by the positive phase III results on brivaracetam. We note that UCB has a strong franchise in epilepsy. The successful development and commercialization of brivaracetam will help strengthen the company's position in the market for epilepsy products.

Investors looking for well-positioned stocks in the biotech sector may consider Biogen Idec Inc. ( BIIB ), which carries a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

VALEANT PHARMA (VRX): Free Stock Analysis Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: VRX , GSK , BIIB , UCBJF



More from Zacks.com:

Related Videos

Spot the Dropout RRC
Spot the Dropout RRC                
Spot the Dropout MG
Spot the Dropout MG                 
Spot the Dropout IPC
Spot the Dropout IPC                



Most Active by Volume

  • $95.21 ▼ 1.84%
  • $18.13 ▼ 0.17%
  • $5.19 ▼ 6.49%
  • $46.88 ▲ 1.27%
  • $3.97 ▲ 0.51%
  • $15.10 ▼ 0.72%
  • $36.08 ▼ 11.61%
  • $122.37 ▼ 0.50%
As of 7/30/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com